Molecular diagnostics laboratory P23 Labs reported on Friday the availability of its new P23 Respiratory ONE test to detect respiratory illnesses that share symptoms with COVID-19 when test results for COVID-19 are negative and the patient is still not healthy.
The company added that the P23 Respiratory ONE can detect the common cold, five different Influenza strains and five Coronavirus strains including COVID-19. The test results are available 48 hours from lab receipt.
According to the company, the P23 Respiratory ONE takes a single COVID-19 sample, whether it is the non-invasive saliva sample or the nasal swab sample. The kits are shipped directly to patients to allow sample collection from the comfort of their own home.
If anyone is presenting COVID-19 symptoms and working with their physician to obtain a COVID-19 order, the patient should also tell their physician that they would like to have a test that identifies what illness they do have if it is not COVID-19, concluded the company.
AstraZeneca launches Phase III THARROS trial for BREZTRI in COPD to assess cardiopulmonary outcomes
Merck finalises acquisition of Harpoon Therapeutics Inc
Pfizer reveals strong efficacy data for ABRYSVO in older adults against RSV
Nuvalent's NVL-520 receives FDA breakthrough therapy designation
Dassault Systèmes enhances patient care with virtual twin experience at Paris hospital
Pulmonx initiates CONVERT II trial for AeriSeal System in COPD treatment
Priority Review of Dupixent underway by FDA for COPD treatment
AstraZeneca boosts vaccine portfolio with acquisition of Icosavax
AstraZeneca reports positive resultsfor Tagrisso in Stage III lung cancer trial
AstraZeneca announces US acceptance of BLA for datopotamab deruxtecan to treat lung cancer
Erasca agrees clinical trial deal with Novartis to study naporafenib in combination with trametinib
FDA accepts Bristol Myers Squibb's Augtyro application for Priority Review